Imfinzi and Spiriva drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Imfinzi (durvalumab) and Spiriva (tiotropium bromide monohydrate). Common drug interactions include death among females and radiation pneumonitis among males.

The phase IV clinical study analyzes what interactions people have when they take Imfinzi and Spiriva. It is created by eHealthMe based on reports of 33 people who take the same drugs from the FDA, and is updated regularly.

What is Imfinzi?

Imfinzi has active ingredients of durvalumab. eHealthMe is studying from 8,353 Imfinzi users. Check the latest studies of Imfinzi.

What is Spiriva?

Spiriva has active ingredients of tiotropium bromide monohydrate. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 156,666 Spiriva users. Check the latest studies of Spiriva.

On Aug, 01, 2026

33 people who take Imfinzi and Spiriva together, and have interactions are studied.

What are the common drug interactions of Imfinzi and Spiriva, by gender? *:

female:

Death
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Pneumonitis (inflammation of the walls of the alveoli in the lungs)
Dyspnoea (difficult or laboured respiration)
Aplasia pure red cell (type of anaemia affecting the precursors to red blood cells but not to white blood cells)
Ataxia (loss of full control of bodily movements)
Blood thyroid stimulating hormone increased
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Cardiac failure
Confusional state

male:

Radiation pneumonitis (inflammation of lung due to radiation)
Diarrhoea
Occult blood positive
Lung disorder (lung disease)
Malignant neoplasm progression (cancer tumour came back)
Productive cough
Interstitial lung disease
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
Escherichia infection (bacterial infection by escherichia coli)
Hepatosplenomegaly (enlargement of both the liver and the spleen)

What are the common drug interactions of Imfinzi and Spiriva, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Aplasia pure red cell (type of anaemia affecting the precursors to red blood cells but not to white blood cells)

60+:

Radiation pneumonitis (inflammation of lung due to radiation)
Diarrhoea
Gastrointestinal oedema (excessive build-up of fluid in the gastrointestinal tract tissues)
Occult blood positive
Lung disorder (lung disease)
Death
Interstitial lung disease
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
Escherichia infection (bacterial infection by escherichia coli)
Hepatosplenomegaly (enlargement of both the liver and the spleen)

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 13 people, 39.39%
High Blood Pressure: 8 people, 24.24%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 18.18%
Lung Cancer - Small Cell (lung cancer): 5 people, 15.15%
Constipation: 4 people, 12.12%
Lung Neoplasm Malignant (cancer tumour of lung): 4 people, 12.12%
Cancer Pain: 4 people, 12.12%
Small Cell Lung Cancer Extensive Stage (small cell lung cancer that has spread (metastasized) to other regions of the body such as another lobe of the lung or the brain): 3 people, 9.09%
Non-Small Cell Lung Cancer Stage Iii: 3 people, 9.09%
Nausea (feeling of having an urge to vomit): 3 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Imfinzi and Spiriva?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously